PM&R Physician Salary Guide 2026: Physiatrist Pay by Setting, EMG & Interventional Spine

Physical medicine and rehabilitation (PM&R) is one of medicine's most procedurally diverse specialties — a physiatrist may spend the morning doing EMG/nerve conduction studies, the afternoon running an acute rehab inpatient ward, and a different day performing fluoroscopy-guided epidural steroid injections. This procedural breadth creates one of the widest compensation ranges among internal medicine-adjacent specialties. In 2026, physiatrist compensation ranges from $220,000 in outpatient non-procedural settings to over $450,000 for interventional spine-focused PM&R physicians with high fluoroscopic procedure volume. This guide covers salary benchmarks by setting, the income impact of EMG and botulinum toxin programs, and the supply-demand dynamics shaping PM&R compensation.

PM&R salary by setting

Practice model and procedural scope are the primary compensation drivers in PM&R:

• Interventional spine and pain PM&R: $300,000–$450,000; fluoroscopy-guided procedures — epidural steroid injections, medial branch blocks, radiofrequency ablation, sacroiliac joint injections — generate the highest wRVU and procedural revenue of any PM&R subspecialty; often practice in ASC or office-based fluoroscopy suite; partial ASC ownership can push total income substantially higher
• Inpatient rehabilitation (acute rehab hospital / IRF): $240,000–$320,000; day-to-day management of post-stroke, TBI, SCI, and post-surgical rehabilitation patients; PM&R attending of record for IRF admission; often shift-based or rounding-based schedule; call responsibility varies by facility
• Spinal cord injury (SCI) specialist: $240,000–$325,000; SCI centers and VA hospitals; complex multi-system management; often IRF-affiliated with academic medical center SCI program
• EMG / electrodiagnostic medicine PM&R: $245,000–$330,000; nerve conduction studies and needle EMG for neuromuscular diagnosis; high wRVU generator; some physiatrists subspecialize primarily in electrodiagnosis within multi-specialty neurology/PM&R groups
• Sports medicine PM&R: $235,000–$320,000; musculoskeletal injury management, US-guided procedures (platelet-rich plasma, prolotherapy, ultrasound-guided injections); team physician relationships add non-clinical income for some sports medicine physiatrists
• Outpatient non-procedural PM&R: $220,000–$295,000; chronic pain management, functional restoration, disability evaluation; lower wRVU ceiling without procedural volume
• Pediatric rehabilitation: $210,000–$280,000; cerebral palsy, pediatric TBI, developmental disabilities, pediatric SCI; botulinum toxin for spasticity management is a key procedural revenue source; concentrated in children's hospitals and pediatric rehab programs
• Academic PM&R: $215,000–$280,000; residency program direction, fellowship training, research; offset by academic prestige and career development opportunities; research grant supplementation available for active investigators

EMG/NCS revenue in PM&R

Electromyography and nerve conduction studies (EMG/NCS) are a significant procedural differentiator for physiatrists who develop electrodiagnostic competency:

• wRVU generation: A complete EMG/NCS study (CPT 95860-95937 series) generates 3–6 wRVUs per study depending on complexity; a physiatrist performing 8–12 EMG studies per week adds 2,000–3,500 wRVUs/year above the E&M baseline
• Income contribution: At $50/wRVU, an active EMG program adds $100,000–$175,000 in annual productivity pay for a physiatrist who has integrated EMG as a regular part of their practice
• Credentialing: ABPMR (American Board of Physical Medicine and Rehabilitation) certifies EMG competency; many physiatrists complete additional focused EMG training during residency or fellowship
• Interpretation-only models: Some physiatrists read EMG studies performed by technicians in remote or telehealth EMG models, generating interpretation revenue with lower time investment than performing studies in-person

Botulinum toxin and spasticity program revenue

Botulinum toxin (Botox, Dysport, Xeomin) injection for spasticity management is one of the highest-yield buy-and-bill procedures available to PM&R physicians:

• Buy-and-bill mechanics: PM&R practices that stock botulinum toxin purchase it at ASP and bill the payer at ASP + markup through J-codes (J0585 for onabotulinumtoxinA, J0586 for abobotulinumtoxinA); each patient session requiring 200–400 units generates meaningful buy-and-bill margin
• Volume scale: A spasticity-focused PM&R practice managing 20–30 botulinum toxin patients per month can generate $80,000–$250,000/year in drug margin, depending on payer mix and unit volumes
• Common spasticity indications: Post-stroke upper and lower limb spasticity, TBI spasticity, cerebral palsy (especially relevant for pediatric PM&R), SCI-related spasticity
• Cosmetic botulinum toxin: Some outpatient physiatrists have incorporated cosmetic botulinum toxin services (outside standard PM&R scope) as a direct-pay revenue stream, though this is a secondary practice model rather than a primary income driver

Interventional spine and ASC ownership

For procedurally-oriented physiatrists pursuing interventional spine practice, ASC (ambulatory surgery center) co-ownership represents the highest income potential in the specialty:

• Physician-owned ASC economics: Each fluoroscopy procedure performed at an ASC generates a facility fee in addition to the professional fee; physician-owners receive a pro-rata share of facility fee revenue based on their ownership percentage and case volume
• Common ASC procedures: Epidural steroid injections (interlaminar and transforaminal), medial branch blocks, radiofrequency ablation of medial branches, sacroiliac joint injections, spinal cord stimulator trials and implants
• Income impact: A physiatrist performing 15–25 fluoroscopic procedures per week with partial ASC ownership can add $100,000–$250,000 in annual facility fee distributions to clinical income, depending on ownership percentage and ASC payer mix

Geographic variation in PM&R compensation

• Sun Belt / high-growth metros (FL, TX, AZ, GA): $280,000–$420,000; high volume of post-surgical rehab, stroke rehabilitation, and aging population driving demand; interventional spine practices well-established
• Northeast: $260,000–$380,000; academic center concentration; strong IRF and SCI center presence; interventional spine competitive
• Midwest / Southeast rural: $250,000–$370,000; IRF access more limited; outpatient PM&R and pain management fill the gap; rural shortage premiums in markets without local physiatrist coverage
• West Coast: $260,000–$390,000; strong sports medicine PM&R market in Pacific Northwest; high COL in major metros

What we see at Ava Health

PM&R is a specialty where the compensation range across settings is larger than what most residents appreciate when they enter fellowship — the difference between an outpatient non-procedural position and a well-structured interventional spine or spasticity-focused practice with buy-and-bill can exceed $150,000/year for the same training. Physiatrists in our network who are entering the job market for the first time frequently undervalue their procedural skills (EMG in particular) and sign purely salary-based offers that don't recognize the wRVU and buy-and-bill contributions they'll generate. We work to make sure candidates have a full picture of the compensation model — not just the headline base salary — before accepting any PM&R position.

Related: Physical Therapist Salary Guide, Occupational Therapist Salary Guide, Internal Medicine Physician Salary Guide, Neurosurgeon Salary Guide.